Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Markowitz

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Cancer Discovery|March 12, 2021
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory MelanomaCara Haymaker, Daniel H Johnson, Ravi Murthy, et al.
Annals of Surgical Oncology|December 8, 2025
ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node BiopsyMichelle M Dugan, Caitlyn Balsay-Patel, Nicholas Chin, et al.
Annals of Surgical Oncology|October 31, 2025
Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node BiopsyMichelle M Dugan, Caitlyn Balsay-Patel, Nicholas Chin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Pigment Cell & Melanoma Research|February 4, 2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesZeynep Eroglu, Sheri L Holmen, Qing Chen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2015
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune CellsSara E Martin del Campo, Kala M Levine, Bethany L Mundy-Bosse, et al.
Nature Cancer|January 23, 2023
Fucosylation of HLA-DRB1 regulates CD4<sup>+</sup> T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacyDaniel K Lester, Chase Burton, Alycia Gardner, et al.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Cancer Discovery|March 12, 2021
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory MelanomaCara Haymaker, Daniel H Johnson, Ravi Murthy, et al.
Annals of Surgical Oncology|December 8, 2025
ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node BiopsyMichelle M Dugan, Caitlyn Balsay-Patel, Nicholas Chin, et al.
Annals of Surgical Oncology|October 31, 2025
Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node BiopsyMichelle M Dugan, Caitlyn Balsay-Patel, Nicholas Chin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Pigment Cell & Melanoma Research|February 4, 2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesZeynep Eroglu, Sheri L Holmen, Qing Chen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2015
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune CellsSara E Martin del Campo, Kala M Levine, Bethany L Mundy-Bosse, et al.
Nature Cancer|January 23, 2023
Fucosylation of HLA-DRB1 regulates CD4<sup>+</sup> T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacyDaniel K Lester, Chase Burton, Alycia Gardner, et al.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
Pageof 9